

DAFTAR PUSTAKA

- Albanese, G. and Kondo, K., 2010. Pharmacology of Sclerotherapy. *SEMINARS IN INTERVENTIONAL RADIOLOGY*, 27(4).
- AlGhamdi, K.M., Ashour, A.E., Rikabi, A.C. and Moussa, N.A., 2014. Phenol as a novel sclerosing agent: A safety and efficacy study on experimental animals. *Saudi Pharmaceutical Journal*, 22(1), pp.71-78.
- AlGhamdi, K. M., Kumar, A., Ashour, A. E., AL-Rikabi, A. C., AlOmrani, A. H., & Ahamed, S. S. (2017). *Vascular sclerosing effects of bleomycin on cutaneous veins: a pharmacopathologic study on experimental animals. Anais Brasileiros de Dermatologia*, 92(4), 484–491. doi:10.1590/abd1806-4841.20175851
- Ali S, Weiss CR, Sinha A, Eng J, Mitchell SE (2016) The treatment of venous malformations with percutaneous sclerotherapy at a single academic medical center. *Phlebology*31:603–609
- Beebe-Dimmer JL, Pfeifer JR, Engle JS, Schottenfeld D. The epidemiology of chronic venous insufficiency and varicose veins. *Annals of epidemiology*. 2005 Mar 1;15(3):175-84.
- Bergan, J. and Bunke, N., 2014. *The Vein Book*. 2nd ed. New York: Oxford University Press, pp.100-15.
- Brittenden, J., Cooper, D., Dimitrova, M., Scotland, G., Cotton, S. C., Elders, A., ... Campbell, M. K. (2019). *Five-Year Outcomes of a Randomized Trial of Treatments for Varicose Veins. New England Journal of Medicine*, 381(10), 912–922. doi:10.1056/nejmoa1805186
- Callam, M.J., 1994. Epidemiology of varicose veins. *British journal of surgery*, 81(2), pp.167-173.
- Churojana, A., 2020. Bleomycin: An effective drug for intralesional injection treatment of vascular anomalies. *Pharm Pharmacol Int J*, 8(1), pp.38-40.
- Eberhardt, R.T. and Raffetto, J.D., 2014. Chronic venous insufficiency. *Circulation*, 130(4), pp.333-346.
- Evans, C.J., Fowkes, F.G., Ruckley, C.V., Lee, A.J., 1999. Prevalence of varicose

veins and chronic venous insufficiency in men and women in the general population: Edinburgh vein study. *J. Epidemiol. Community Health* 53 (3), 149–153.

Fukaya, E., Flores, A. M., Lindholm, D., Gustafsson, S., Zanetti, D., Ingelsson, E., & Leeper, N. J. (2018). Clinical and Genetic Determinants of Varicose Veins. *Circulation*, 138(25), 2869–2880. doi:10.1161/circulationaha.118.035584

Gibson, K., & Gunderson, K. (2018). Liquid and Foam Sclerotherapy for Spider and Varicose Veins. *Surgical Clinics of North America*, 98(2), 415–429. doi:10.1016/j.suc.2017.11.010

Goldman, M. P. (1987). *Sclerosing Agents in the Treatment of Telangiectasia. Archives of Dermatology*, 123(9), 1196. doi:10.1001/archderm.1987.01660330107021

Goldman, M. P. (2002). *Treatment of Varicose and Telangiectatic Leg Veins: Double-Blind Prospective Comparative Trial Between Aethoxyskerol and Sotradecol. Dermatologic Surgery*, 28(1), 52–55. doi:10.1046/j.1524-4725.2002.01190.x

Hassan Y, Osman AK, Altyeb A. 2013. Noninvasive management of hemangioma and vascular malformation using intralesional bleomycin injection. *AnnPlastSurg*70:70–73

Helal, H.A. and Mahmoud, N.A., 2020. Effect of foam and liquid bleomycin in the management of venous malformations in head and neck region: a comparative study. *Journal of Plastic, Reconstructive & Aesthetic Surgery*, 73(1), pp.90-97.

Horbach, S. E. R., Rigter, I. M., Smitt, J. H. S., Reekers, J. A., Spuls, P. I., & van der Horst, C. M. A. M. (2016). *Intralesional Bleomycin Injections for Vascular Malformations. Plastic and Reconstructive Surgery*, 137(1), 244–256. doi:10.1097/prs.0000000000001924

Ismail, L., Normahani, P., Standfield, N.J. and Jaffer, U., 2016. A systematic review and meta-analysis of the risk for development of varicose veins in women with

- a history of pregnancy. *Journal of Vascular Surgery: Venous and Lymphatic Disorders*, 4(4), pp.518-524.
- Jacobs, B. N., Andraska, E. A., Obi, A. T., & Wakefield, T. W. (2017). Pathophysiology of varicose veins. *Journal of Vascular Surgery: Venous and Lymphatic Disorders*, 5(3), 460–467. doi:10.1016/j.jvsv.2016.12.014
- Kahle, B., & Leng, K. (2004). *Efficacy of Sclerotherapy in Varicose Veins-A Prospective, Blinded, Placebo-Controlled Study. Dermatologic Surgery*, 30(5), 723–728. doi:10.1111/j.1524-4725.2004.30207.x
- Khan, D. and Ahmed, D., 2019. A prospective study on etiology and clinical features of varicose veins: A hospital based study. *International Journal of Surgery Science*, 3(4), pp.06-10.
- Kremastiotis, J., Jfri, A., Litvinov, I.V., Barolet, D. and Netchiporouk, E., 2020. Treatment Modalities for Varicose Veins of Lower Extremities. *Journal of cutaneous medicine and surgery*, 24(2), pp.203-204.
- Li, N., Li, J., Huang, M. and Zhang, X., 2021. *Efficacy and safety of polidocanol in the treatment of varicose veins of lower extremities: a protocol for systematic review and meta-analysis*. *Medicine* 2021; 100:8(e24500).
- Lurie, F., Passman, M., Meisner, M., Dalsing, M, et al., 2020. The 2020 update of the CEAP classification system and reporting standards. *Journal of Vascular Surgery: Venous and Lymphatic Disorders*, 8(3), pp.342-352.
- Mahmoud, N., 2019. Effect of Foam and Liquid Bleomycin in the Management of Venous Malformations in Head and Neck Region. A Comparative Study. *Egypt, J. Plast. Reconstr. Surg*, 43(3), pp.401-408.
- Mack, J. M., Richter, G. T., Becton, D., Salem, O., Hill, S. E. M., & Crary, S. E. (2018). *Short-term side effects and patient-reported outcomes of bleomycin sclerotherapy in vascular malformations. Pediatric Blood & Cancer*, 65(6), e27008. doi:10.1002/pbc.27008
- Mallick, R., Raju, A. and Campbell, C., 2015. Treatment Patterns and Outcomes in Patients with Varicose Veins. *Am Health Drug Benefits*, 9(8), pp.455-465.

- Mohammad, A., 2019. Study on prevalence, demographic and clinical manifestations of lower limb varicose veins. *International Journal of Surgery*, 3(4), pp.272-274.
- MOL, W., FURUKAWA, H., SASAKI, S., TOMARU, U., HAYASHI, T., SAITO, A., ... YAMAMOTO, Y. (2007). *Evaluation of the Sclerotherapeutic Efficacy of Ethanol, Polidocanol, and OK-432 Using an In Vitro Model. Dermatologic Surgery*, 0(0), 071009211231009-??? doi:10.1111/j.1524-4725.2007.33315.x
- Parsons, M., 2004. Sclerotherapy basics. *Dermatologic Clinics*, 22(4), pp.501-508.
- Pedrycz, A. and Budzyńska, B., 2016. Diagnosis of varicose veins of the lower limbs – functional tests. *Arch Physiother Glob Res*, 20(3), pp.29-32.
- Rabe, E., Schliephake, D., Otto, J., et al. (2010) Sclerotherapy of Telangiectases and Reticular Veins: A Double-Blind, Randomized, Comparative Clinical Trial of Polidocanol, Sodium Tetradecyl Sulphate and Isotonic Saline (EASI Study). *Phlebology*, 25, 124-131. <https://doi.org/10.1258/phleb.2009.009043>
- Raetz, J., Wilson, M. and Collins, K., 2019. Varicose Veins: Diagnosis and Treatment. *Am Fam Physician*, 99(11), pp.682-688.
- Roselli, A., Khouri, C., Roustit, M., Blaise, S. and Cracowski, J.L., 2019. Safety profile of sclerosing agents: an analysis from the world health organization pharmacovigilance database Vigibase. *Dermatologic Surgery*, 45(12), pp.1517-1528.
- Sadick, N. and Li, C., 2001. SMALL_VESSEL SCLEROTHERAPY. *Dermatologic Clinics*, 19(3), pp.475-481.
- Sainsbury DC, Kessell G, Fall AJ, Hampton FJ, Guhan A, Muir T (2011) Intralesional bleomycin injection treatment for vascular birthmarks: a 5-year experience at a single United Kingdom unit. *Plast Reconstr Surg* 127:2031–2044
- Tisi, P. V., Beverley, C., & Rees, A. (2006). *Injection sclerotherapy for varicose veins. Cochrane Database of Systematic Reviews*.

Lampiran 1

KEMENTERIAN PENDIDIKAN, KEBUDAYAAN, RISET DAN TEKNOLOGI
UNIVERSITAS HASANUDDIN FAKULTAS KEDOKTERAN
KOMITE ETIK PENELITIAN KESEHATAN
RSFTN UNIVERSITAS HASANUDDIN
RSUP Dr. WAHIDIN SUDIROHUSODO MAKASSAR
Sekretariat : Lantai 2 Gedung Laboratorium Terpadu
JL.PERINTIS KEMERDEKAAN KAMPUS TAMALANREA KM.10 MAKASSAR 90245.
Contact Person: dr. Agusalm Bukhari, M.Med,Ph.D., Sp.GK, TELP. 081241830858, 0411 5790103, Fax : 0411-581431

REKOMENDASI PERSETUJUAN ETIK

Nomor : 63/UN4.6.4.5.31/ PP36/ 2022

Tanggal: 8 Februari 2022

Dengan ini Menyatakan bahwa Protokol dan Dokumen yang Berhubungan Dengan Protokol berikut ini telah mendapatkan Persetujuan Etik :

No Protokol	UH21110694		No Sponsor Protokol	
Peneliti Utama	dr. Benny Nanda Kurniawan		Sponsor	
Judul Peneliti	EFEK SCLEROSIS VASKULAR DENGAN AGEN POLIDOCANOL, BLEOMYCIN DAN ETHANOL 95%. STUDI PENELITIAN PATOLOGI ANATOMI PADA BINATANG PERCOBAAN KELINCI JAWA (LEPUS NIGRICOLLIS)			
No Versi Protokol	2	Tanggal Versi	7 Pebruari 2022	
No Versi PSP		Tanggal Versi		
Tempat Penelitian	Laboratorium Hewan FKUH dan Laboratorium HUM-RC Makassar			
Jenis Review	<input type="checkbox"/> Exempted <input checked="" type="checkbox"/> Expedited <input type="checkbox"/> Fullboard Tanggal		Masa Berlaku	Frekuensi review lanjutan
Ketua KEPK FKUH RSUH dan RSWS	Nama Prof.Dr.dr. Suryani As'ad, M.Sc.,Sp.GK (K)		Tanda tangan	
Sekretaris KEPK FKUH RSUH dan RSWS	Nama dr. Agusalm Bukhari, M.Med.,Ph.D.,Sp.GK (K)		Tanda tangan	

Kewajiban Peneliti Utama:

- Menyerahkan Amandemen Protokol untuk persetujuan sebelum di implementasikan
- Menyerahkan Laporan SAE ke Komisi Etik dalam 24 jam dan dilengkapi dalam 7 hari dan Laporan SUSAR dalam 72 jam setelah Peneliti Utama menerima laporan
- Menyerahkan Laporan Kemajuan (progress report) setiap 6 bulan untuk penelitian resiko tinggi dan setiap setahun untuk penelitian resiko rendah
- Menyerahkan laporan akhir setelah Penelitian berakhir
- Melaporkan penyimpangan dari protokol yang disetujui (protocol deviation / violation)
- Mematuhi semua peraturan yang ditentukan

Lampiran 2

NO	KODE	INFLAMASI	PROLIFERASI	PENYEMPITAN LUMEN	FIBROSIS	Total
1	B1	0	0	4	0	4
2	B2	0	1	2	0	3
3	B3	1	1	2	1	5
4	B4	1	1	2	0	4
5	B5	3	1	4	2	10
6	B6	0	1	0	0	1
7	B7	0	1	4	0	5
8	B8	1	1	0	0	2
9	B9	0	0	0	0	0
10	B10	0	1	4	2	7
11	B11	1	1	2	1	5
12	B12	0	0	0	0	0
13	B13	0	1	1	1	3
14	B14	0	0	0	0	0
15	B15	0	0	0	0	0
16	B16	0	1	4	2	7
17	P1	0	1	0	0	1
18	P2	0	1	1	0	2
19	P3	0	0	0	0	0
20	P4	0	1	0	0	1
21	P5	0	1	0	0	1
22	P6	0	1	0	0	1
23	P7	1	1	0	1	3
24	P8	1	1	3	1	6
25	P9	0	0	0	0	0
26	P10	1	0	0	0	1
27	P11	2	1	4	2	9
28	P12	0	1	4	2	7
29	P13	0	0	0	0	0
30	P14	1	0	4	2	7
31	P15	0	1	0	0	1
32	P16	0	1	1	1	3
33	E1	0	0	0	0	0
34	E2	0	0	0	0	0
35	E3	1	1	0	0	2
36	E4	0	1	0	0	1

37	E5	0	1	4	2	7
38	E6	0	1	2	0	3
39	E7	0	1	0	0	1
40	E8	0	1	0	0	1
41	E9	1	0	3	2	6
42	E10	1	1	4	2	8
43	E11	0	0	2	1	3
44	E12	0	1	1	0	2
45	E13	0	0	1	0	1
46	E14	1	0	1	1	3
47	E15	3	1	4	2	10
48	E16	3	1	2	2	8

Data Penelitian			INFLAMASI (Lapang Pandang)			Proliferasi Vascular		Penyempitan Lumen				Fibrosis			T O T A L		
N O	K O D E	PERLAKUAN (WAKTU PENGAMBILAN SAMPSEL)	Tid ak ad a	1 L P	2 L P	> 3 L P	Tid ak ad a	sedi kit (1L P)	Tid ak ad a	< 2 5 %	26 - 50 %	51 - 75 %	75 - 100 %	Tid ak ad a		1 L P	> 2 L P
			0	1	2	3	0	1	0	1	2	3	4	0	1	2	
1	B 1	BLEOMISIN 1 JAM	x				x						x	x			4
2	B 2	BLEOMISIN 1 JAM	x					x			x			x			3
3	B 3	BLEOMISIN 1 JAM		x				x			x				x		5
4	B 4	BLEOMISIN 1 JAM		x				x			x			x			4
5	B 5	BLEOMISIN 24 JAM				x		x					x			x	1 0
6	B 6	BLEOMISIN 24 JAM	x					x	x					x			1
7	B 7	BLEOMISIN 24 JAM	x					x					x	x			5
8	B 8	BLEOMISIN 24 JAM		x				x	x					x			2
9	B 9	BLEOMISIN 7 HARI	x				x		x					x			0
10	B 0	BLEOMISIN 7 HARI	x					x					x			x	7
11	B 1	BLEOMISIN 7 HARI		x				x			x				x		5

1 2	B 1 2	BLEOMISIN 7 HARI	x				x		x					x			0
1 3	B 1 3	BLEOMISIN 45 HARI	x					x		x					x		3
1 4	B 1 4	BLEOMISIN 45 HARI	x				x		x					x			0
1 5	B 1 5	BLEOMISIN 45 HARI	x				x		x					x			0
1 6	B 1 6	BLEOMISIN 45 HARI	x					x						x		x	7
1 7	P 1	POLIDOCANOL 1 JAM	x					x	x					x			1
1 8	P 2	POLIDOCANOL 1 JAM	x					x		x				x			2
1 9	P 3	POLIDOCANOL 1 JAM	x				x		x					x			0
2 0	P 4	POLIDOCANOL 1 JAM	x					x	x					x			1
2 1	P 5	POLIDOCANOL 24 JAM	x					x	x					x			1
2 2	P 6	POLIDOCANOL 24 JAM	x					x	x					x			1
2 3	P 7	POLIDOCANOL 24 JAM		x				x	x						x		3
2 4	P 8	POLIDOCANOL 24 JAM	x					x				x			x		6
2 5	P 9	POLIDOCANOL 7 HARI	x				x		x					x			0
2 6	P 0	POLIDOCANOL 7 HARI		x			x		x					x			1
2 7	P 1	POLIDOCANOL 7 HARI			x			x						x		x	9
2 8	P 2	POLIDOCANOL 7 HARI	x					x						x		x	7
2 9	P 3	POLIDOCANOL 45 HARI	x				x		x					x			0
3 0	P 4	POLIDOCANOL 45 HARI		x			x							x		x	7
3 1	P 5	POLIDOCANOL 45 HARI	x					x	x					x			1
3 2	P 6	POLIDOCANOL 45 HARI	x					x		x					x		3
3 3	E 1	ETANOL 1 JAM	x				x		x					x			0

CURRICULUM VITAE

A. Data Pribadi

Nama : dr.Benny Nanda Kurniawan
Tempat/Tanggal Lahir : Bandar Lampung, 11 Desember 1991
Alamat : Rusunawa 1 Unhas
Agama : Katholik

B. Riwayat Pendidikan

- SD : Sekolah Fransiskus Xaverius
- SMP : Sekolah Fransiskus Xaverius
- SMA : Sekolah Fransiskus Asisi
- Strata-1 (Pendidikan Dokter) : Fakultas Kedokteran Universitas Atma Jaya, lulus tahun 2015
- Program Pendidikan Dokter Spesialis-1 : Departemen Ilmu Bedah Fakultas Kedokteran Universitas Hasanuddin Periode Jan 2018

C. Riwayat Pekerjaan

- Dokter Umum RSUD Prof. Dr. H. Aloi Saboe Kota Gorontalo

D. Riwayat Keluarga

- Ayah : Iwan Kurniawan
- Ibu : Septiana
- Saudara Kandung : Tomi Nanda Kurniawan, Aldi Nanda Kurniawan
- Istri : dr. Silvia Suminto

E. Karya Ilmiah/Artikel yang telah dipublikasikan

Review article: Nocturnal Hypertension: Neglected Issue in Comprehensive Hypertension Management (dipublikasi pada Acta Medica Indonesiana)

Penelitian: RIPASA score terhadap appendicitis komplikata dan non komplikata (dipublikasi pada Majalah Viva Medica Gorontalo)

Ekstrak Saw Palmetto Sebagai Terapi Ajuvan *Benign Prostate Hyperplasia* : Tinjauan Pustaka (dalam proses publikasi pada Cermin Dunia Kedokteran)

F. Makalah pada Seminar/ Konferensi ilmiah Nasional dan Internasional

Congenital Vaginouterine Prolapse without Spinal Anomaly : A Case Report
(dipresentasikan pada Pertemuan Ilmiah Tahunan IKABI Jakarta 2017)

Vesicolithiasis in Pediatric : A Case Report

(dipresentasikan pada Pertemuan Ilmiah Tahunan IKABI Jakarta 2017)

Penile Squamous Cell Carcinoma : A Case Report

(dipresentasikan pada Pertemuan Ilmiah Tahunan IKABI Jakarta 2017)

Choledocolithiasis in pediatric: a case report

(dipresentasikan pada Pertemuan Ilmiah Tahunan IKABI Pekanbaru 2019)

The Effect of Stromal Vascular Fraction (SVF) And Platelet-Rich Plasma (PRP) Combination On Basic Fibroblast Growth Factor (bFGF) Serum Level During Anal Trauma Healing in A Wistar Rat Model

(dipresentasikan pada PIT PERBANI Semarang 2022)